KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Total Liabilities (2018 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Total Liabilities for 8 consecutive years, with $161.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Liabilities changed 0.25% year-over-year to $161.8 million, compared with a TTM value of $161.8 million through Sep 2025, changed 0.25%, and an annual FY2024 reading of $173.2 million, up 1.8% over the prior year.
  • Total Liabilities was $161.8 million for Q3 2025 at Aurinia Pharmaceuticals, down from $167.3 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $173.2 million in Q4 2024 and bottomed at -$448.1 million in Q1 2022.
  • Average Total Liabilities over 5 years is $87.0 million, with a median of $154.7 million recorded in 2025.
  • The sharpest move saw Total Liabilities tumbled 1056.51% in 2022, then skyrocketed 168.26% in 2023.
  • Year by year, Total Liabilities stood at $64.3 million in 2021, then increased by 1.79% to $65.4 million in 2022, then soared by 160.0% to $170.1 million in 2023, then rose by 1.8% to $173.2 million in 2024, then dropped by 6.59% to $161.8 million in 2025.
  • Business Quant data shows Total Liabilities for AUPH at $161.8 million in Q3 2025, $167.3 million in Q2 2025, and $154.7 million in Q1 2025.